CGMs without diabetes: feedback is not yet an outcome

Decide what you want to learn

A glucose graph makes an invisible process visible. That is the attraction of a continuous monitor for someone without diabetes: immediate feedback after a meal or activity. The missing step is whether acting on that feedback improves health. An engaging trace and a proven preventive intervention are different things.

A sensible starting question is limited and specific: would temporary monitoring help you understand a pattern you can discuss with a clinician? Continuous purchase is a separate decision. Neither the availability of a device nor the detail of its graph establishes that indefinite monitoring is useful for every healthy adult.

What healthy reference data show

Shah and colleagues studied CGM profiles in 153 healthy participants aged 7–80 using a blinded sensor protocol. Median time between 70 and 140 mg/dL was 96 percent. The study describes glucose patterns in a selected nondiabetic population; it did not randomize participants to act on visible readings or show that suppressing every excursion improves health. Because children were included, it is also not exclusively an adult reference sample. ^[1]

Reference distributions help explain variation. They are not instructions to turn a normal physiological response into a treatment target. The method, participant selection and monitoring duration affect what a reference graph means.

What FDA clearance actually covers

The FDA's 2024 Stelo announcement describes an over-the-counter system intended for adults who do not use insulin, including people without diabetes interested in diet and activity effects. It also states that people should not make medical decisions from the output without talking with a healthcare provider. The original clearance excluded people with problematic hypoglycemia because the system does not provide the needed warning function. Product labeling should be checked for the current intended use. ^[2]

Clearance supports a defined device use. It does not mean the FDA has established that healthy consumers who follow app suggestions live longer or that proprietary wellness scores are clinical treatment targets.

Understand what a curve leaves out

A glucose trace is one dimension of a meal's effect. It does not directly measure nutritional adequacy, satiety, cardiovascular risk or whether a dietary pattern is sustainable. Judging food only by the height of a glucose rise can therefore answer the wrong question. A comparison also becomes difficult when portion size, activity, meal timing and other conditions differ.

For personal observations, keep a simple record of the relevant context instead of treating each peak as a verdict. A few readings cannot establish an individual food intolerance or a disease. Avoid changing medication or undertaking restrictive eating based on an app interpretation.

Screening is a different clinical pathway

The USPSTF recommends screening for prediabetes and type 2 diabetes in asymptomatic adults aged 35–70 who have overweight or obesity, with consideration of additional risk factors. Its screening methods include established laboratory approaches such as fasting glucose and HbA1c. The recommendation is not a direction for everyone in that age range to buy a consumer CGM. ^[3]

If your concern is diabetes risk, ask which clinical test answers that question and what follow-up is appropriate. A reassuring two-week trace does not substitute for a clinician's interpretation of symptoms, risk factors or laboratory findings.

Put a boundary around the experiment

Before buying, review intended-use exclusions, phone compatibility, replacement policy and the commitment required. Advertised wear duration is a maximum, so learn what happens when a sensor fails early. For recurring plans, distinguish a monthly shipment from a prepaid multi-month order and record the renewal date.

Set a point at which you will review whether the information helped. If the graph increases anxiety, prompts unnecessary food avoidance or produces repeated unexplained readings, more data may not be the useful next step. Our Stelo and Lingo comparison separates access and billing details from claims about clinical benefit.

For a fair budget, also distinguish a four-week supply from a calendar month; the difference accumulates over a year of replacement purchases.